Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies

Abstract

Though the remission rate and survival of patients failing venetoclax are poor, a small proportion of these R/R AML patients may still respond to cautious intensification of chemotherapy with venetoclax.